uniQure (NASDAQ:QURE) Upgraded by Wells Fargo & Company to Overweight Rating

Wells Fargo & Company upgraded shares of uniQure (NASDAQ:QURE) from an equal weight rating to an overweight rating in a research report released on Monday morning, MarketBeat reports. The brokerage currently has $60.00 target price on the biotechnology company’s stock, up from their prior target price of $15.00.

A number of other brokerages also recently commented on QURE. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. The Goldman Sachs Group lowered their price target on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Finally, Wolfe Research started coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, uniQure presently has an average rating of “Hold” and a consensus price target of $41.33.

uniQure Trading Up 26.1%

Shares of NASDAQ QURE opened at $17.99 on Monday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a one year low of $7.76 and a one year high of $71.50. The business has a 50-day moving average price of $21.90 and a two-hundred day moving average price of $29.64. The firm has a market capitalization of $1.12 billion, a PE ratio of -5.21 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 14,581 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the transaction, the chief executive officer directly owned 660,658 shares in the company, valued at approximately $5,985,561.48. The trade was a 2.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the transaction, the insider owned 138,483 shares in the company, valued at $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 81,399 shares of company stock worth $1,527,645. Insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Woodline Partners LP increased its position in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of uniQure in the second quarter valued at approximately $151,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of uniQure in the second quarter valued at approximately $215,000. SG Americas Securities LLC acquired a new stake in shares of uniQure in the second quarter worth $1,321,000. Finally, Main Management ETF Advisors LLC increased its position in uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 912 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Analyst upgrades and price‑target increases lifting sentiment — Wells Fargo upgraded QURE to “overweight” with a $60 PT and Chardan boosted its PT to $31 with a buy rating; RBC moved to “outperform” with a $35 PT. These calls drove constructive re‑ratings and buy-side interest. Wells Fargo Upgrade Chardan PT Raise
• Positive Sentiment: Regulatory leadership change in the FDA (CBER director Vinay Prasad’s announced exit) is being interpreted by the market as easing near‑term regulatory risk for gene‑therapy programs, prompting a sector rally that lifted uniQure shares. Blockonomi: Stock Soars on FDA Exit Benzinga: Biotech Reaction
• Neutral Sentiment: Analyst and media coverage is spotlighting uniQure ahead of key AMT‑130 catalysts; these pieces increase visibility but do not change fundamentals absent clinical or regulatory news. 24/7 Wall St. Analyst Interest
• Negative Sentiment: Multiple law firms have filed or publicized investor notices seeking lead plaintiffs for a securities class action covering Sept. 24–Oct. 31, 2025 (claims tied to AMT‑130 disclosures). The proliferation of filings (Faruqi, Hagens Berman, Levi & Korsinsky, Portnoy, Rosen) creates legal and disclosure risk and could impose costs or settlement pressure. Faruqi & Faruqi Notice Hagens Berman Alert Levi & Korsinsky Notice Portnoy Law Firm Rosen Law Firm Notice
• Negative Sentiment: Coverage highlighting “confusion” and shifting narratives around uniQure’s disputes with the FDA over AMT‑130 suggests ongoing regulatory uncertainty that could weigh on valuation until resolved. The Pharma Letter: Confusion Grows Yahoo Finance: Shifting Narrative

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.